You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Focal Tumour Ablation for Renal Cell Carcinoma

ID: FA3 Aug 2016
Type of Content: Guidelines & Advice, Evidence Summary
Document Status: Current
J. Kachura, F. Baldassarre, A. Kielar, M. Baerlocher, The Interventional Oncology Steering Committee

Guideline Objective

The objective of this evidence review was to determine the effectiveness of focal tumour ablation, including radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation therapy (CAT) for the treatment of patients with localized renal cell carcinoma (RCC) by providing a systematic literature review that will be one of the six components of the Recommendation Report being developed by the Interventional Oncology Steering Committee. The additional components to their report are demand forecasting, costing analysis, jurisdictional review, system capacity, and current state.

Patient Population

Patients with localized, non-metastatic renal cell carcinoma.

Intended Guideline Users

Interventional radiologists, radiation oncologists, urological surgeons, medical oncologists, and healthcare professionals caring for patients with RCC.

Research Question(s)

  1. What is the effectiveness of focal ablation for the treatment of patients with RCC?
  2. What are the toxicities associated with focal ablation for RCC?
  3. What patient populations are most likely to benefit from focal ablation for RCC?
pdf download Full Report (PDF) (513.36 KB)